RICHMOND, Va., Feb. 27,
2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE:
INDV) has appointed Joe
Ciaffoni, currently an Independent Non-Executive Director of
the Company, as Chief Executive Officer. The terms of his
appointment are subject to, and effective upon, the approval by
shareholders of a new remuneration policy at the Company's AGM in
May 2025.
Mr. Ciaffoni, 53, was appointed as an Independent Non-Executive
Director to Indivior's Board in December
2024. He is a proven public company CEO with more than 30
years of experience in pharmaceuticals and biotech, working in both
global and US organizations. He has a strong track record of
operational and strategic success, working across diverse models
and therapeutic areas spanning specialty, rare disease, mass market
and hospital. He most recently served as President and CEO of
Collegium Pharmaceutical and has held senior roles as Endo
International, Biogen and Shionogi Inc.
By mutual agreement, Mark
Crossley will be stepping down as Chief Executive Officer
and as a Board Director following a distinguished tenure leading
the Company. Mark will remain with Indivior to support the
transition, ensuring stability and continuity for the business, and
is expected to remain as CEO until at least the date of the
Company's AGM in May 2025.
David Wheadon, Chair of
Indivior's Board of Directors, said: "We are delighted to
appoint Joe as our next Chief Executive Officer. He is an
accomplished leader with a strong track record of delivering
positive outcomes for patients while generating shareholder value.
He has a clear mandate to fuel the next stage of Indivior's growth
and deliver on the Company's significant potential and we look
forward to supporting his success as CEO."
Joe Ciaffoni said: "It is
an honor to be appointed as CEO. Indivior is a leader in the
addiction treatment space and its work has never been more
necessary. I look forward to working with the team to deliver on
the Company's potential and to drive Indivior's future growth for
the benefit of all our stakeholders".
Mark was appointed as CEO in June
2020. Under his stewardship, the Company has strengthened
its commitment to patients, expanded access to treatment, and
advanced its mission of pioneering life-transforming treatments for
substance use disorders.
David Wheadon said: "On
behalf of the Board of Directors, I would like to thank Mark for
his many contributions to Indivior and wish him the best in his
future endeavors. His integrity and commitment to our patients and
the people of Indivior will leave a lasting impact."
Mark Crossley said: "It
has been a tremendous privilege to have worked at Indivior over the
last decade, the last five as CEO. I truly believe in our vision
and commitment to helping our patients and widening access to
treatment, a belief I know is shared by the many incredible
colleagues across the business. I am proud of the pivotal role
Indivior plays in combatting one of the great human crises of our
lifetime and I wish the business every success going
forward."
About Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD). Our vision is
that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to expand on its heritage in this category. Headquartered in
the United States in Richmond, VA, Indivior employs over 1,000
individuals globally and its portfolio of products is available in
over 30 countries worldwide. Visit www.indivior.com to learn more.
Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
For Further Information
Investor
Inquiries
Jason
Thompson
VP, Investor Relations,
Indivior PLC
804-402-7123
Jason.thompson@indivior.com
Tim
Owens
Director, Investor Relations, Indivior
PLC
804-263-3978
Timothy.owens@indivior.com
UK Media
Inquiries
Jonathan
Sibun
Teneo
+44 (0)20 7353
4200
Indivior@teneo.com
U.S. Media
Inquiries
Cassie France-Kelly
VP,
Communications, Indivior PLC
Cassie.france-kelly@indivior.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/indivior-announces-joseph-ciaffoni-appointed-chief-executive-officer-302387004.html
SOURCE Indivior PLC
